Home›US Markets›Sectors›FDA approval for pancreatic cancer drug could spur wav…

FDA approval for pancreatic cancer drug could spur wave of similar treatments

Companies are testing dozens of related drugs across pancreatic, lung, colon and other cancers, potentially expanding the treatment pipeline beyond the first approved therapy.

Reported · Written up by our desk · Sectors

A new drug approved by the U.S. Food and Drug Administration for pancreatic cancer could be a starting point for a broader wave of similar treatments, according to the New York Times.

The outlet reports that multiple companies are already running tests on dozens of comparable drugs aimed at cancers including pancreatic, lung, and colon.

With the first approval potentially validating the approach, the focus for investors and patients may shift toward how quickly additional candidates advance through clinical testing and whether they can replicate the benefits of the newly approved therapy.

More like this

Sources